What is the projected global sales revenue for the orphan drug market by the year 2032 according to Evaluate's report?

According to the report published by Evaluate, the global orphan drug market is projected to exceed 400 billion dollars by 2032.

What percentage of global prescription drug sales is the orphan drug market expected to account for by 2032?

The orphan drug market is expected to account for over 21% of all global prescription drug sales by the year 2032.

Key products Darzalex and Vyvgart are expected to lead the market, with Darzalex estimated to reach 31 billion dollars in sales.

Argenx and Merck are poised for high growth, while Bristol Myers Squibb faces orphan drug challenges due to patent expirations.

Policy incentives such as the Inflation Reduction Act and the reauthorization of Priority Review Vouchers continue to support innovation.

AI News NQ Analysis

NQ Score 88/100

Evaluate發布2032年孤兒藥市場展望報告，預測屆時該市場將佔全球處方藥銷售額21%以上，規模突破4000億美元。

AI analysis data is not yet available.

Q: What is the projected global sales revenue for the orphan drug market by the year 2032 according to Evaluate's report?: A: According to the report published by Evaluate, the global orphan drug market is projected to exceed 400 billion dollars by 2032.
Q: What percentage of global prescription drug sales is the orphan drug market expected to account for by 2032?: A: The orphan drug market is expected to account for over 21% of all global prescription drug sales by the year 2032.
Q: Which specific orphan drug products are projected to lead the global market, and what is the sales estimate for Darzalex?: A: Key products Darzalex and Vyvgart are expected to lead the market, with Darzalex estimated to reach 31 billion dollars in sales.
Q: Which pharmaceutical companies are poised for high growth in the orphan drug sector, and which company faces patent expiration challenges?: A: Argenx and Merck are poised for high growth, while Bristol Myers Squibb faces orphan drug challenges due to patent expirations.
Q: What specific government policy incentives continue to support innovation in the global orphan drug market according to Evaluate?: A: Policy incentives such as the Inflation Reduction Act and the reauthorization of Priority Review Vouchers continue to support innovation.